The Portex CorrectInject safety system is designed for the administering of neuraxial (spinal and epidural) medication. It is intended to help reduce the risk of tubing misconnections, while minimizing changes to clinical technique.
“We are pleased to be able to offer a solution that help to reduce medication delivery errors during spinal and epidural anaesthesia administration,” said Smiths Medical President Srini Seshadri, in the release. “As a global leader of safety medical devices, it is our obligation to develop innovative medical products that not only help protect patients when they are most vulnerable but help to raise clinical standards of care.”
The Portex CorrectInject system for epidural anaesthesia injection is the first of the line to be cleared for market release in the United States. The CorrectInject safety system for spinal anaesthesia administration is available in the United Kingdom, Ireland, Australia and countries in Asia. Smiths Medical intends to expand regionalized introductions of the CorrectInject system, including a system for epidural infusion, as country registrations and approvals are granted.
Smiths Medical’s worldwide headquarters is in St. Paul, Minn.
Related Articles on FDA Clearances:
Teleflex Receives FDA Clearance for Preloaded Peripherally Inserted Central Catheter
BD Diagnostics Receives FDA Clearance for New Influenza Test
InnerOptic Receives FDA Clearance for Needle-Based Interventions ‘GPS’
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.